268 related articles for article (PubMed ID: 23676198)
21. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
[TBL] [Abstract][Full Text] [Related]
22. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH
J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098
[TBL] [Abstract][Full Text] [Related]
23. Anxiety, depressive symptom and suicidal ideation of outpatients with obsessive compulsive disorders in Taiwan.
Hung TC; Tang HS; Chiu CH; Chen YY; Chou KR; Chiou HC; Chang HJ
J Clin Nurs; 2010 Nov; 19(21-22):3092-101. PubMed ID: 21040015
[TBL] [Abstract][Full Text] [Related]
24. Registered clinical trials investigating ketamine for psychiatric disorders.
Peyrovian B; McIntyre RS; Phan L; Lui LMW; Gill H; Majeed A; Chen-Li D; Nasri F; Rosenblat JD
J Psychiatr Res; 2020 Aug; 127():1-12. PubMed ID: 32315806
[TBL] [Abstract][Full Text] [Related]
25. Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Lengvenyte A; Strumila R; Olié E; Courtet P
Eur Neuropsychopharmacol; 2022 Apr; 57():88-104. PubMed ID: 35219097
[TBL] [Abstract][Full Text] [Related]
26. Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression.
Hochschild A; Keilp JG; Madden SP; Burke AK; Mann JJ; Grunebaum MF
J Affect Disord; 2022 Mar; 300():10-16. PubMed ID: 34953926
[TBL] [Abstract][Full Text] [Related]
27. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
[TBL] [Abstract][Full Text] [Related]
28. Ketamine for Depression, 2: Diagnostic and Contextual Indications.
Andrade C
J Clin Psychiatry; 2017 May; 78(5):e555-e558. PubMed ID: 28570803
[TBL] [Abstract][Full Text] [Related]
29. Intravenous ketamine for treatment-resistant major depressive disorder.
Covvey JR; Crawford AN; Lowe DK
Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
[TBL] [Abstract][Full Text] [Related]
30. The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.
Lee JH; Dunner DL
Depress Anxiety; 2008; 25(2):91-7. PubMed ID: 17311265
[TBL] [Abstract][Full Text] [Related]
31. Suicidality in obsessive compulsive disorder (OCD): a systematic review and meta-analysis.
Angelakis I; Gooding P; Tarrier N; Panagioti M
Clin Psychol Rev; 2015 Jul; 39():1-15. PubMed ID: 25875222
[TBL] [Abstract][Full Text] [Related]
32. Maintenance therapy with electroconvulsive therapy in a patient with a codiagnosis of bipolar disorder and obsessive-compulsive disorder.
Bülbül F; Copoglu US; Alpak G; Unal A; Tastan MF; Savas HA
J ECT; 2013 Jun; 29(2):e21-2. PubMed ID: 23519221
[TBL] [Abstract][Full Text] [Related]
33. Impact of depressive and anxiety disorder comorbidity on the clinical expression of obsessive-compulsive disorder.
Viswanath B; Narayanaswamy JC; Rajkumar RP; Cherian AV; Kandavel T; Math SB; Reddy YC
Compr Psychiatry; 2012 Aug; 53(6):775-82. PubMed ID: 22136738
[TBL] [Abstract][Full Text] [Related]
34. Aripiprazole in depersonalization disorder comorbid with major depression and obsessive-compulsive disorder: 3 cases.
Uguz F; Sahingoz M
Clin Neuropharmacol; 2014; 37(4):125-7. PubMed ID: 24992087
[TBL] [Abstract][Full Text] [Related]
35. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
36. Body dysmorphic disorder in patients with obsessive-compulsive disorder: prevalence and clinical correlates.
Conceição Costa DL; Chagas Assunção M; Arzeno Ferrão Y; Archetti Conrado L; Hajaj Gonzalez C; Franklin Fontenelle L; Fossaluza V; Constantino Miguel E; Rodrigues Torres A; Gedanke Shavitt R
Depress Anxiety; 2012 Nov; 29(11):966-75. PubMed ID: 22815241
[TBL] [Abstract][Full Text] [Related]
37. Ketamine-induced affective switch in a patient with treatment-resistant depression.
Banwari G; Desai P; Patidar P
Indian J Pharmacol; 2015; 47(4):454-5. PubMed ID: 26288483
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
aan het Rot M; Collins KA; Murrough JW; Perez AM; Reich DL; Charney DS; Mathew SJ
Biol Psychiatry; 2010 Jan; 67(2):139-45. PubMed ID: 19897179
[TBL] [Abstract][Full Text] [Related]
39. Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior.
Chan LF; Eu CL; Soh SY; Maniam T; Shahidii Kadir Z; Chong BTW; Loo JL; Sharip S; Wong VCW; Loo TH; Ng YP; Kahn DA
J Psychiatr Pract; 2018 Jul; 24(4):279-291. PubMed ID: 30427812
[TBL] [Abstract][Full Text] [Related]
40. Short-term ketamine administration in treatment-resistant depression patients: focus on adverse effects on the central nervous system.
Włodarczyk A; Cubała WJ; Szarmach J; Małyszko A; Wiglusz MS
Psychiatr Danub; 2019 Sep; 31(Suppl 3):530-533. PubMed ID: 31488786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
